The MITOCARE study evaluated the efficacy and safety of TRO40303 for the reduction of reperfusion injury in patients undergoing revascularization for ST-elevation myocardial infarction (STEMI).
Introduction
Reperfusion injury, which can occur following primary percutaneous coronary intervention (PCI) for an acute ST-elevation myocardial infarction (STEMI), arises when circulation to ischaemic tissue is restored. This effect is thought to cause considerable harm, accounting for as much as half of the final infarct size, 1 as well as increasing the likelihood of subsequent mortality and the occurrence of other major cardiac events. 2 Efforts continue to search for safe and effective strategies to mitigate reperfusion injury with the aim of improving clinical outcomes in patients undergoing primary PCI for STEMI. A number of approaches have suggested a potential to reduce infarct size within the context of PCI for STEMI. In a randomized clinical trial, the compound FX06 was shown to reduce the necrotic core zone; however, there were no significant differences in total infarct size measured by TnI levels, late gadolinium enhancement (LGE) cardiac magnetic resonance (CMR) imaging, or CK-MB (creatine kinase-myocardial band) activity. 3 Cyclosporine A, on the other hand, was associated with significant reductions in both infarct size and plasma CK levels, but not in plasma TnI levels. 4 Exenatide reduced infarct size in patients with short-treatment delay. 5 Other strategies such as therapeutic hypothermia 6 -7 and postconditioning 8 -10 have not consistently shown benefit, even if confounding factors could have hidden the effects. 11 Conditioning protocols have been successfully used in patients undergoing PCI, 12 and particularly remote ischaemic conditioning has shown very promising results 13 -14 but needs to be initiated before reperfusion. 15 As of today, interventions tested so far to reduce cardiac reperfusion injury have not led to unequivocal recommendations for routine use in clinical praxis. Whether this is due to clinical trial design issues and/or a lack of sufficient measurable harm due to reperfusion injury in man is not clarified. The mitochondrial permeability transition pore (mPTP) is believed to be a promising target for preventing reperfusion injury. 16 -18 TRO40303 inhibits mPTP opening and has been shown to reduce infarct size in animal models of myocardial infarction, 19 -20 indicating a potential to mitigate ischaemic reperfusion injury and the subsequent negative effects. Of note, the compound has shown efficacy in protecting human cells (data not shown), thus supporting a potential translation in human. Since January 2011, the MITOCARE consortium, comprised of 17 Europe-based teams of experts specializing in clinical and basic research, biomarkers, imaging, and informatics, has been investigating the efficacy and safety of TRO40303 as adjunct to standard cardiac care for the reduction of reperfusion injury among patients who present with early STEMI and undergo primary PCI.
Methods
Between October 2011 and September 2013, we conducted a prospective, multicentre, randomized, double-blind, placebo-controlled, phase IIa, proof-of-concept study in 10 clinical trial centres of four European countries. The rationale and study design have been published previously. 21 Briefly, the MITOCARE study (clinicaltrialsregister.eu; EudraCT number 2010-024616-33) randomized patients with STEMI necessitating primary PCI to TRO40303 or placebo via i.v. bolus injection just prior to balloon inflation. The study complies with the Declaration of Helsinki and was approved by Regulatory Agencies and local Ethics Committees. Because of potential discrepancies between endpoints of cardiac injury, complementary biomarkers including CK and TnI as well as CMR were measured.
Patients
The study population included patients .18 years of age with a firsttime STEMI (defined as nitrate resistant chest pain ≥30 min, and new ST elevation at J-point in two contiguous leads with cut-off points: ≥0.2 mV in men or ≥0.15 mV in women in leads V2-V3 and/or ≥0.1 mV in other leads). Additional inclusion criteria were presentation within 6 h of the onset of chest pain, clinical decision to treat with PCI, occlusion of culprit artery (left anterior descending artery, or dominant or balanced right coronary artery, or dominant or balanced left circumflex artery) with thrombolysis in myocardial infarction (TIMI) flow grade 0-1 at time of admission and before PCI, and being of non-child-bearing potential. Patients were excluded if they had experienced cardiac arrest, ventricular fibrillation, cardiogenic shock, stent thrombosis, a previous acute myocardial infarction (AMI), angina within 48 h before infarction, previous coronary artery bypass graft (CABG), i.v. fibrinolytic therapy within 72 h prior to PCI, atrial fibrillation, had a pacemaker, concurrent inflammatory, infectious, or malignant disease, or a biliary obstruction or hepatic insufficiency. A signed informed consent to participate was obtained prior to any study-related procedure, or within 12/24 h post-procedure if oral consent was provided beforehand (France/ Norway).
Procedures
Eligible patients were randomly assigned to receive either TRO40303 or placebo after coronary angiography, but just before balloon inflation, during PCI. Patients received concomitant medications according to the current standard of cardiac care. Treatment units, available in the cat-lab as ready to use i.v. solutions, were taken in ascending and consecutive order in each infarction stratum (anterior/posterior as determined on ECG) in order to ensure equal randomization. An injection of either the study medication, TRO40303 (6 mg/kg), or placebo was given via i.v. slow bolus (35 mL/min; given over 1 min) to patients before guide wire passage, 15 min (and preferably 5 min) prior to balloon inflation and stenting.
Cardiovascular magnetic resonance
Cardiovascular magnetic resonance was performed on whole-body 1.5 T MR scanners in a supine position with ECG-gated image acquisition. Approximately 5 min after an i.v. injection of 0.2 mmol/kg of a gadolinium-based contrast agent, contrast-enhanced steady-statefree precession (CE-SSFP) short-axis cine images covering the entire left ventricle as well as two-, three-, and four-chamber long-axis cine images (image resolution 8 × 1.5 × 1.5 mm) were acquired. Approximately 15 min after injection of the contrast agent, late gadolinium-enhanced (LGE) images (image resolution 8 × 1.5 × 1.5 mm, no slice gap) were acquired in the corresponding imaging planes as for the CE-SSFP images using an inversion-recovery gradient-recalled echo sequence. Inversion time was manually adjusted to null the signal from remote myocardium. 22 
Outcomes
The primary outcome measure, infarct size, was expressed as area under the curve for CK and for TnI calculated over a 3-day period (AUC (0 -72) The main secondary outcome measure was infarct size normalized to the myocardium at risk expressed as a myocardium salvage index (MSI ¼ 1-infarct size/myocardium at risk). Cardiac magnetic resonance images were acquired 3 -5 days after the acute infarction. Myocardium at risk and left ventricular function were assessed by contrast-enhanced-steady-state-free precession cine imaging. 23, 24 Infarct size for secondary outcome purposes was assessed by LGE CMR. 25 All CMR analyses were performed by a core laboratory (Imacor AB, Lund, Sweden; www.imacor.se) blinded to all clinical data. Other secondary outcomes included measures of left ventricular function post-PCI evaluated using CMR or echocardiography performed along with CMR and repeated at Day 30. A novel electronic case report form was utilized on iPad. Additional biomarkers, as detailed in the previous publication, 21 were assessed for use in subanalyses evaluating potential confounders as well as a prognostic value. Safety assessments included physical examination, vital signs, and laboratory tests. Physical examination, vital signs, and ECG were conducted at baseline, 1, 24, 48, and 72 h, as well as Day 30. Timing of lab tests varied depending on the parameter. ST-elevation myocardial infarction cardiovascular complications and suspected unexpected serious adverse reaction were adjudicated by a Clinical Event Committee that included three cardiologists coordinated by the Uppsala Clinical Research Center who were not participants in the study.
Statistical analysis
Based on the data by Piot et al.,
4 sample size calculation of n ¼ 83 per group allowed a 85% power to detect an effect size (i.e. difference in mean AUCs/standard deviation) of 0.47 using a two-sided test with a type I error of 0.05. The primary endpoint was compared between treatment groups using an analysis of covariance (ANCOVA) mixed model. Treatment was considered as a fixed effect and the centre as a random effect, with time to PCI and culprit artery being used as covariables. Linear interpolation was used for the imputation of a missing value between two recorded values; otherwise a multiple imputation technique was used based on patient characteristics (treatment, age, sex, infarct localization, post-PCI TIMI-flow).
The comparison of CMR data for the secondary endpoints was conducted similarly for all parameters, with the exception of the myocardial salvage index (MSI), for which culprit artery was not included in the model. All efficacy analyses were performed on the intention-to-treat (ITT) and per-protocol populations. The cumulative incidences of adverse clinical events between treatment groups were analysed using Fisher's exact test and reported for the safety population. All statistical analyses were performed using the SAS 9.2 software. Additional post hoc analyses were performed using the same software or GraphPad Prism 5 for the t-test and x 2 test.
Results
A total of 167 patients were randomized (1 : 1) to receive either TRO40303 or placebo prior to undergoing PCI. Four patients were excluded (two patients failed to meet inclusion criteria and did not receive treatment, and two patients in the TRO40303 group were treated but did not undergo PCI, one received CABG and one had a coronary dissection), leaving 163 patients in the ITT population treated by PCI and of whom 83 received TRO40303 and 80 received placebo ( Figure 1) . The two patients having received TRO40303 without being treated by PCI were included in the safety population (n ¼ 165). There were generally no differences in patient characteristics at baseline between groups ( Table 1) , although the median age was older in the TRO40303 group (63.8 years) compared with the placebo group (60.0 years). Approximately 60% of patients had posterior infarctions and median pain-to-balloon time was 180 min in both groups. The median (mean) door-to-balloon time was 60 (38) min at all sites, which shows that there was no delay in the study due to randomization and compound administration. The distribution of culprit vessel was comparable; with the right coronary artery (dominant or balanced) being the site of occlusion in about half of patients. Use of concomitant medication was similar between groups (not shown), and no patients received isoflurane or propofol. However, the rate of unsuccessful PCI as indicated by TIMI flow grade 0 or 1 of the culprit artery post-PCI was higher in the TRO40303 group (12 vs. 6.3% with placebo, not statistically different by the x 2 test).
On admission, mean (+ SD) CK levels (U/L) (273.36 + 410.80 and 161.18 + 144.29) were numerically higher in the TRO40303 group than in the placebo group (P ¼ 0.065) ( Table 1) . There were no significant differences between TRO40303 and placebo in the co-primary measures of efficacy, infarct size expressed as AUC (0 -72) (mean + SD 77558.4 + 50058.7 vs. 74455.3 + 54601.9, P ¼ 0.98) and infarct size expressed as AUC for TnI over 3 days (mean + SD 3377.6 + 3031.7 vs. 3084.9 + 2838.1, P ¼ 0.57) (Figure 2) .
All CMR measures were validated for 93 patients (50 in the TRO40303 group and 43 in the placebo group) and included in the mixed model ANCOVA assessment of secondary efficacy measures. This was due to a combination of lost to follow-up, consent withdrawal for CMR linked to claustrophobia, data acquisition failure and technical issues such as patients too large for the CMR procedure. Worth of note, all results have been verified on this subgroup (demography and infarct size assessed by biomarkers) in a post hoc analysis, and identical results as for the whole trial population were found. The main secondary endpoint of mean MSI (1-infarct size/ myocardium at risk) was not significantly different between the TRO40303 and placebo groups (mean 52 and 58%, respectively, P ¼ 0.1000). There were no significant differences in mean CMR-assessed infarct size (21.9 g vs. 20.0 g or 17 vs. 15% of LV-mass) or left ventricular ejection fractions (LVEF) (46 vs. 48%) between TRO40303 and placebo. Differences between treatment groups in the remaining CMR secondary outcome measures, with the exception of infarct transmurality (mean TRO40303, 75 and placebo, 70%; P ¼ 0.004), were not significant ( Table 2) . Similarly, there were no significant differences in the mean 30-day echocardiographic LVEF (51.5 vs. 52.2%) or the other Day 3-5 and Day 30 echocardiographic secondary endpoints ( Table 3) .
The cumulative incidence of major adverse events adjudicated by the clinical events committee for the safety population (n ¼ 165) is shown in Table 4 . Overall, 37 events occurred in 29 patients, with 26 events in 21 (24.7%) patients in the TRO40303 group and 11 events in 8 (10.0%) patients in the placebo group (P ¼ 0.013 for proportion of patients with at least one event). The most common events in both treatment groups were ventricular arrhythmias, revascularization, and cardiogenic shock.
There were 102 serious adverse events (SAEs), of which 72 occurred in 35 (41.2%) patients in the TRO40303 group and 30 occurred in 20 (25%) patients in the placebo group indicating that some patients experienced several SAEs that occurred consecutively. More than half of the SAEs in both groups were cardiac disorders ( Table 5) , which occurred twice as often in the TRO40303 group compared with the placebo group (36 vs. 17 events). The number of events considered by the investigators to be possibly related to the study medication and not to the consequence of underlying factors linked to cardiovascular disorders and consequences of myocardial infarction (cardiac disorders, surgical and medical procedures, vascular disorders, familial and genetic disorders excluded) was 18 in the TRO40303 group and 8 in the placebo group.
Discussion
The MITOCARE study of TRO40303 failed to show reductions in infarct size as measured by the co-primary endpoints of reduction in AUC (0 -72) for the cardiac biomarkers CK and TnI. Analysis of secondary endpoints as measured by CMR and echocardiography confirmed that there were no significant differences between TRO40303 and placebo in reducing reperfusion injury. The likelihood to have missed an effect due to a type II error is considered to be low as the trial was sufficiently powered for the primary endpoint. However, the study was not powered for safety analysis, yet it revealed a higher rate of cardiac events in the TRO40303 group. Hence, the possibility that this imbalance in adverse events is linked to the study drug cannot be ruled out. The overall mortality seen in the study was comparable with those seen in similar recent trial, which is reassuring regarding the general safety of the patients.
When comparing the size of the infarcts measured in the MITO-CARE trial to previous trails, it turns out they are relatively small. Compared with the cyclosporine-A study 4 the serum CK levels
(maximum values between 4 and 8 h post-PCI) in the current MITOCARE study were closer to those in the active (cyclosporine-A) treatment arm than to the considerably higher values in the placebo arm. Additionally, compared with hypothermia trials, 6 -7 the infarcts measured by CMR expressed as IS/MAR were similar for TRO40303 (48%) and the placebo groups of the RAPID MI-ICE and CHILL-MI trials (47 -52%), whereas the placebo group in MITOCARE (42%) was similar to the hypothermia arms of these trials (30 -41%). This suggests no deleterious effects of TRO40303 and that the standard of care including the prehospital AMI-logistics in the MITOCARE might have influenced the result. Indeed, the achievement of very fast reperfusion and preservation of the left ventricle, as documented by the 30-day echocardiographic LVEF, appears to leave limited room for further infarct size reduction. These results combined with the many failures in the field raise a more provocative additional issue: whether reperfusion injury occurs at all in man and-if it does-whether this type of injury really does account for a significant part of the remaining infarct. If the truth lies in two negative answers, the investigation into therapies directed at reducing reperfusion injury would have to undergo particular scrutiny in the future.
An important factor in the treatment of STEMI patients for longterm outcome is the rate of successful recanalization of the occluded culprit vessel. In our study, there was an unexpected difference in the proportion of patients having a TIMI flow grade 0-1 after primary PCI. This is most likely due to a play of chance. However, this may explain the somewhat higher figure of SAEs such as death, . ............ ............ ............ ............ ........... ............ ............ ............ ........... ............ ............ ............ ........... ............ .... cardiogenic shock, heart failure, and ventricular arrhythmias observed in the TRO40303 arm of the trial. Of note, this difference could conceivably also indicate a deleterious or pro-thrombotic effect of the treatment, even though such an effect was not seen in the previous phase I study. 12, 13 Against this notions speaks the fact that no stent thrombosis occurred in either of the two treatment groups, and there was no effect on prothrombin time (PT) (mean 27.96 s vs. 30.45 s between TRO40303 and placebo), activated Study limitations include the fact that although most baseline characteristics were well balanced between the two groups, the initial mean CK level trended higher in the TRO40303 group. This reflects a potential bias in favour of the placebo group that most likely occurred by chance at inclusion, with more severe cardiac distress being disproportionately represented in the TRO40303 group. The median age of patients in the TRO40303 was approximately 4 years older than those in the placebo group, which also may have contributed to the higher rate of SAEs in that group. In addition, only one dose of TRO40303 was tested in the trial and even if unlikely, there is a possibility that the tested dose was not appropriate.
In conclusion, the phase II MITOCARE study examined the potential for adjunctive TRO40303 to limit reperfusion injury in patients undergoing primary PCI for STEMI, using state-of-the art therapeutic principles. The primary endpoint was not met, and this evidence implies that treatment of STEMI patients with immediate mechanical revascularization and contemporary supportive pharmacotherapy does not lend support for TRO40303 to limit reperfusion injury of the infarcted myocardium. Further research is needed to provide additional insight into the nature of reperfusion injury.
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